ISSUE 90 I JANUARY 2020

ACCESS DENIED:

the impact trial

Is NHS England putting patients at risk by restricting access to pre-exposure prophylaxis drugs?

In association with

The burden of endometriosis

The scourge of fake medicines in Africa

Big pharma's presence in China

In association with

02/24/2024 09:36:19

12/18/2019 00:00:00

Go to article: Home | Access denied: the Impact trial Go to article: Scandinavian Health Ltd.Go to article: In this issue Go to article: Emirates SkyCargo Go to article: Contents Go to article: News Go to article: Fargo Go to article: The pharma industry briefing Go to article: Phoenix Company Insight Go to article: Phoenix Go to article: Breast cancer timeline: charting three decades of success Go to article: PrEP drugs: is the NHS letting down patients at risk of HIV?Go to article: Swiss WorldCargo Go to article: Debate: can US pharma be taxed into behaving?Go to article: LB Bohle Company Insight Go to article: LB Bohle Go to article: Can new therapies tackle the burden of endometriosis?Go to article: The rise of fake medicines in Africa Go to article: Zenatek Go to article: Off-the-shelf CAR-T therapy: broadening the reach of precision medicine Go to article: Nobel Prize 2019: how a breathtaking discovery unlocked new drugs Go to article: Pfanstiehl Company Insight Go to article: Pfanstiehl Go to article: China in 2019: a prime destination for R&D deals Go to article: The global-local continuum: tips for a joined-up approach to Regulatory & PV out Go to article: Pharmacovigilance 2.0: reskilling for the digital & data science age Go to article: Air France KLM Cargo Go to article: Deals in brief powered by GlobalData Go to article: The key list powered by GlobalData Go to article: Events Go to article: Next issue